Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Call for abstracts
Programme
Tracks
Speakers
Side events
Venue
About the venue
Rooms
Subscribe
days
hours
minutes
seconds
Medicines
Sessions
Wednesday, 23 November
09:00
Ensuring adequate pain relief whilst reducing addiction risk: lessons learnt and the way forward
09:00
to
10:30
Main stage
Sarah Welch
10:50
Improving knowledge, taking action
10:50
to
12:20
Networking zone 1 (N1)
Eilish Gilvarry
Prescription opioids and overdose deaths
10:50
to
12:20
Knowledge market 1 (K1)
Thomas Clausen
Substance-induced psychosis: register-linkage research in Nordic countries
10:50
to
12:20
Knowledge market 2 (K2)
Solja Niemelä
13:20
e-/m-health interventions for substance use disorders
13:20
to
14:50
Central square 3 (C3)
Peter J. Adams
Precision Medicine and Novel Approaches to the Treatment Alcohol Use Disorder
13:20
to
14:50
Central square 1 (C1)
Katie Witkiewitz
15:00
Drug Early Warning Systems – the key to preparedness and response to new psychoactive substances
15:00
to
16:30
Central square 2 (C2)
Ana Gallegos,
Roumen Sedefov
Estimating harm
15:00
to
16:30
Central square 3 (C3)
Xavier Majó Roca
Short communications on alcohol: Covid, Ketamine, Cognition, Consumption
15:00
to
16:30
Networking zone 3 (N3)
Cristina Ribeiro
16:50
Driving under the influence of cannabis (DUIC)
16:50
to
18:20
Insights zone 3 (I3)
Jan Ramaekers
Improving the health of people who use drugs
16:50
to
18:20
Networking zone 4 (N4)
Magdalena Harris
Thursday, 24 November
09:00
Contemporary Issues
09:00
to
10:30
Central square 2 (C2)
Anne Line Bretteville-Jensen
10:50
Interventions in Community
10:50
to
12:20
Networking zone 1 (N1)
Elena Gervilla
Practitioners informing practice
10:50
to
12:20
Knowledge market 3 (K3)
Gerhard Buhringer
13:20
Uppers, downers and psychedelics
13:20
to
14:50
Networking zone 3 (N3)
Harry Sumnall
16:50
New frontiers to regulating cannabis for public health and social justice
16:50
to
18:20
Insights zone 2 (I2)
Simon Lenton
Trajectories of cannabis use during periods of policy change
16:50
to
18:20
Central square 2 (C2)
Rosalie Pacula
Friday, 25 November
13:20
Understanding drug use, risk and harm
13:20
to
14:50
Networking zone 2 (N2)
Henrique Lopes
Presentations
e-poster
Methamphetamine Addiction in the South- East Nigeria And The Community Approach : The Way Forward
Networking zone 1 (N1)
Gladys Chibuzor
e-poster
Risk reduction and health promotion for transgender substance users: a systematic review of activist literature
Networking zone 1 (N1)
Anna Baleige
Short communication
Cognitive Functions in Early- Detoxified Alcohol-Dependent Inpatients and Their Association with Severity of Alcohol Dependence
Networking zone 3 (N3)
Prabhoo Dayal
Short communication
Efficacy of Cognitive Retraining Module for improving Cognitive Deficits of abstinent patients with Alcohol Dependence Syndrome and Opioid Dependence Syndrome in a Tertiary Care De-addiction Centre of Northern India
Networking zone 3 (N3)
Gauri Shanker Kaloiya
Oral presentation
Peer and Nursing-led Outreach Combined with Point-of-care HCV Testing to Decentralise HCV Care and Enhance HCV Treatment Among People Who Use Drugs: The REACH_U Project
Networking zone 4 (N4)
Cristiana Merendeiro
Short communication
Peer involvement and intersectoral cooperation experiences in outreach work with people who use psychoactive substances: a scoping review
Networking zone 4 (N4)
João Pedro Ramos
e-poster
Prolonged DAM-take-home in times of Covid-19:harm reduction or increase?
Networking zone 1 (N1)
Franciska Brezan
Oral presentation
Medical cannabis in professional education: Assessment of students from Malta, Israel and Russia
Knowledge market 3 (K3)
Yuval Zolotov
e-poster
Changes in sexualised and non-sexualised drug use among LGBT+ people during the COVID-19 pandemic: A systematic review
Networking zone 2 (N2)
Dean Connolly
e-poster
Abuse of prescription psychoactive medicines
Networking zone 2 (N2)
Darja Lavtar
e-poster
Suicide and self-harm among people prescribed opioid agonist treatment in New South Wales: a retrospective data linkage study
Networking zone 2 (N2)
Samantha Colledge-Frisby
Wednesday, 23 November
09:00
Keynote presentation
Pain and the opioid overdose crisis in the U.S.: experiences, lessons learned, and the path forward
09:00
to
10:30
Main stage
Christopher M. Jones
Keynote presentation
Changing perspectives on the use of medicines for pain
09:00
to
10:30
Main stage
Cathy Stannard
Keynote presentation
EFIC recommendations: When to use opioids for chronic pain and when not to
09:00
to
10:30
Main stage
Winfried Häuser
10:50
Oral presentation
4. Substance-induced psychosis and later schizophrenia or bipolar disorder: transition rates and the role of infections
10:50
to
12:20
Knowledge market 2 (K2)
Jørgen G. Bramness
Oral presentation
5. Antipsychotic use and associating factors among persons with substance-induced psychosis and first-episode psychosis. A nationwide register-linkage study
10:50
to
12:20
Knowledge market 2 (K2)
Jeyaniroshan Jeyapalan
Oral presentation
1. Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016
10:50
to
12:20
Knowledge market 2 (K2)
Eline Borger Rognli
Oral presentation
2. Characteristics of incident substance-induced psychosis compared to incident first episode psychosis. A nationwide register-linkage study
10:50
to
12:20
Knowledge market 2 (K2)
Pihla Sassi
Oral presentation
3. Relapse rate of substance-induced psychosis and associated risk factors. A nationwide registerlinkage study
10:50
to
12:20
Knowledge market 2 (K2)
Heidi Taipale
Oral presentation
1. Characteristics of suicides among overdose deaths in Norway in 2016-2020
10:50
to
12:20
Knowledge market 1 (K1)
Hilde Marie Erøy Edvardsen
Oral presentation
2. Individuals dying of overdoses related to pharmaceutical opioids differ from individuals dying of overdoses related to other substances
10:50
to
12:20
Knowledge market 1 (K1)
Svetlana Skurtveit
Oral presentation
3. Changes in primary cause of overdose deaths following liberalisations in opioid prescription practices and differences in overdose death correlates.
10:50
to
12:20
Knowledge market 1 (K1)
Linn Gjersing
Oral presentation
4. Fatal overdoses in a cohort of chronic pain patients
10:50
to
12:20
Knowledge market 1 (K1)
Aleksi Hamina
e-poster
Prevalence of HCV infection in vulnerable populations: DETECT-C program a real contribution to hepatitis C elimination in these groups in Spain
10:50
to
12:20
Networking zone 1 (N1)
Francisco Pascual
e-poster
ABC Training for Alcohol Use During an Abstinence Challenge (IkPas/NoThanks!): a pilot study
10:50
to
12:20
Networking zone 1 (N1)
Ting Pan
e-poster
Drug death related bereavement and recovery (The END-project)
10:50
to
12:20
Networking zone 1 (N1)
Birthe Møgster
e-poster
Effects of prolonged diacetylmorphine take-home prescription in Heroin assisted treatment in Switzerland
10:50
to
12:20
Networking zone 1 (N1)
Jonas Montagna
e-poster
Predicting the long-term effect of e-cigarette use on population health: A systematic review of modelling studies
10:50
to
12:20
Networking zone 1 (N1)
Giang Vu
e-poster
Barriers and Facilitators to Accessing Inpatient and Community Substance Use Treatment and Harm Reduction Services for People Who Use Drugs in Muslim Communities: A Systematic Narrative Review of Studies on Service Users and Providers Experiences
10:50
to
12:20
Networking zone 1 (N1)
Qutba Al Ghafri
13:20
Oral presentation
1. ABC-Training: A New Proposition-Based Variety of Cognitive Bias Modification. Theoretical Background and Initial Results.
13:20
to
14:50
Central square 1 (C1)
Reinout W. Wiers
Oral presentation
2. Phenotyping Individuals with Alcohol Use Disorder: Implications for Precision Medicine and Predicting Non-Abstinent Recovery from Alcohol Use Disorder
13:20
to
14:50
Central square 1 (C1)
Katie Witkiewitz
Oral presentation
3. Examining a Brief Measure and Observed Cutoff Scores to Identify Reward and Relief Drinking Profiles: Psychometric Properties and Pharmacotherapy Response
13:20
to
14:50
Central square 1 (C1)
Victoria R. Votaw
Discussion
New Directions in Behavioral and Pharmacological Treatments and Precision Medicine Approaches for Improving Rates of Recovery from Alcohol Use Disorder
13:20
to
14:50
Central square 1 (C1)
Karl Mann
Oral presentation
Discontinuing chronic benzodiazepine use for insomnia with blended care: results of a pragmatic cluster-RCT
13:20
to
14:50
Central square 3 (C3)
Kristien Coteur
Oral presentation
A cluster randomised controlled trial of an eHealth intervention to prevent multiple lifestyle risk behaviours among Australian adolescents: Results from the Health4Life Study
13:20
to
14:50
Central square 3 (C3)
Katrina Champion
Oral presentation
Digital technologies to prevent drug overdoses. A UK perspective
13:20
to
14:50
Central square 3 (C3)
Alberto Oteo
Oral presentation
Feasibility and efficacy of the S-Check App to change help seeking behaviour of people who use methamphetamine
13:20
to
14:50
Central square 3 (C3)
Krista Siefried
15:00
Short communication
Changes in retrospectively recalled alcohol use and hazardous drinking pre, during, and post an alcohol sales prohibition in Botswana during COVID pandemic.
15:00
to
16:30
Networking zone 3 (N3)
J. Maphisa Maphisa
Short communication
Exploring the potential for Managed Alcohol Programmes during the COVID-19 pandemic in Scotland: Findings from a mixed methods study
15:00
to
16:30
Networking zone 3 (N3)
Hannah Carver
Short communication
Consumption of alcohol, tobacco and lifestyles in the population over 50 years old: Perception of quality and satisfaction with life
15:00
to
16:30
Networking zone 3 (N3)
Filipa Coelhoso
Short communication
Managed alcohol program in the low-threshold daily facility in the City of Brno, Czech Republic.
15:00
to
16:30
Networking zone 3 (N3)
Petr Blažek
Short communication
Thirty years of experience in Alcoholism treatment
15:00
to
16:30
Networking zone 3 (N3)
Inês Azevedo Silva
Short communication
This Is Something That Changed My Life': A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders
15:00
to
16:30
Networking zone 3 (N3)
Merve Mollaahmetoglu
Oral presentation
It is logically not possible to quantify the number of indirect deaths
15:00
to
16:30
Central square 3 (C3)
Alfred Uhl
Oral presentation
Mortality and Morbidity in Patients in Opioid Maintenance Treatment
15:00
to
16:30
Central square 3 (C3)
Roman Gabrhelík
Oral presentation
Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment and race and ethnicity for the United States 2000-2018.
15:00
to
16:30
Central square 3 (C3)
Charlotte Buckley
Oral presentation
Mortality consequences of misuse of psychoactive prescription drugs in Portugal - the MisuMedPT project
15:00
to
16:30
Central square 3 (C3)
Ana Araújo
Oral presentation
5. International cooperation to address global public health harms caused by novel psychoactive substances while protecting access to medicines
15:00
to
16:30
Central square 2 (C2)
Dilkushi Poovendran
Oral presentation
1. Early warning on emerging drug threats at the international level – opportunities and challenges
15:00
to
16:30
Central square 2 (C2)
Martin Raithelhuber
Oral presentation
2. Global markets, glocal threats: Early warning, preparedness, and response to new psychoactive substances in Europe
15:00
to
16:30
Central square 2 (C2)
Michael Evans-Brown
Oral presentation
3. Early Warning Systems are Critical to Drug Control Strategies to Protect Public Health and Safety
15:00
to
16:30
Central square 2 (C2)
Luli R. Akinfiresoye,
Terrence L. Boos
Oral presentation
4. NPS Discovery: An Open Access Early Warning System for the United States
15:00
to
16:30
Central square 2 (C2)
Barry K. Logan
Oral presentation
Utilising data linkage to describe and explore mortality among a retrospective cohort of individuals admitted to residential substance use treatment.
15:00
to
16:30
Central square 3 (C3)
Tisdale Calvert
16:50
Short communication
Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double dummy, randomised, controlled trial
16:50
to
18:20
Networking zone 4 (N4)
Arne Skulberg
Short communication
Monitoring overall mortality among people who are using drugs in Europe: A good practice example for international cooperation via the REITOX network
16:50
to
18:20
Networking zone 4 (N4)
Tanja Schwarz
Short communication
Developing an Intervention to Manage Benzodiazepine Dependence and High-Risk Use in the Context of Escalating Drug Related Deaths: A feasibility study
16:50
to
18:20
Networking zone 4 (N4)
Catriona Matheson
Short communication
Housing-based syringe services programs to improve access to safe injecting supplies for people who inject drugs in Vancouver, Canada: A spatially-oriented qualitative study
16:50
to
18:20
Networking zone 4 (N4)
Koharu Loulou Chayama
Short communication
Registration for opioid agonist treatment in Ireland from 1999 to 2019: positive findings in younger individuals.
16:50
to
18:20
Networking zone 4 (N4)
Peter McCarron
Short communication
The role of a medically supervised injecting room in improving access to health and social services.
16:50
to
18:20
Networking zone 4 (N4)
Nico Clark
Oral presentation
5. Medical use and novel cannabinoids
16:50
to
18:20
Insights zone 3 (I3)
Robyn Robertson
Oral presentation
1. Experimental studies on cannabis and driving impairment
16:50
to
18:20
Insights zone 3 (I3)
Tom Arkell
Oral presentation
2. Epidemiological studies on cannabis and crash risk
16:50
to
18:20
Insights zone 3 (I3)
Eef Theunissen
Oral presentation
3. Toxicology: detection of THC impairment
16:50
to
18:20
Insights zone 3 (I3)
Jan Ramaekers
Oral presentation
4. Policy and legislation
16:50
to
18:20
Insights zone 3 (I3)
Brendan Hughes
Short communication
Barriers and facilitators for use of oral healthcare services among people with substance use disorders: A qualitative study in Norway
16:50
to
18:20
Networking zone 4 (N4)
Siv-Elin Carlsen
Thursday, 24 November
09:00
Oral presentation
Stakeholders’ perceptions about their position and the dynamics between the stakeholders within Swedish drug policy field
09:00
to
10:30
Central square 2 (C2)
Tuulia Lerkkanen
Oral presentation
Switching from a criminalisation to a public health approach to injecting drug use in Eastern Europe and Central Asia: a modelling analysis of the costs and impact on HIV transmission
09:00
to
10:30
Central square 2 (C2)
Zoe Ward
Oral presentation
Addressing intimate partner abuse (IPA) perpetrated by heterosexual men in substance use treatment: the ADVANCE programme
09:00
to
10:30
Central square 2 (C2)
Gail Gilchrist
Oral presentation
ROSE: A peer-led intervention to support peer workers in overdose response settings in British Columbia
09:00
to
10:30
Central square 2 (C2)
Fred Cameron
10:50
e-poster
Bridges in Prevention: a community-based multi-component intervention model
10:50
to
12:20
Networking zone 1 (N1)
Carla Frazão
e-poster
Non-medical use of ADHD medication among Dutch college students
10:50
to
12:20
Networking zone 1 (N1)
Michelle van der Horst
e-poster
SIPAFS Platform - A contribution to the Digital Transformation of the Plano Operacional deRepostas Integradas
10:50
to
12:20
Networking zone 1 (N1)
Bruno Freitas
e-poster
Police, firefighters, urban cleaners, drivers, gardeners and gravediggers and risk behaviors related to Alcohol, Tobacco, Obesity and Sleep: different professions, different consumption, different interventions?
10:50
to
12:20
Networking zone 1 (N1)
Jorge Barroso-Dias
e-poster
Training of trainers and monitoring implementation of evidence based drug prevention in Pakistan
10:50
to
12:20
Networking zone 1 (N1)
Johan Jongbloet
e-poster
French chemsex project
10:50
to
12:20
Networking zone 1 (N1)
Jonathan Rayneau
e-poster
Process evaluation of the Belgian one-month-abstinence campaign ‘Tournée Minérale’
10:50
to
12:20
Networking zone 1 (N1)
Annelies Thienpondt
e-poster
When substance use meets sexuality: perspectives of gays, bisexuals and men having sex with men (gbMSM) regarding their sexualized drug use
10:50
to
12:20
Networking zone 1 (N1)
Maxime Blanchette
Oral presentation
Administration matters! A retrospective cohort study of medication dispensing at pharmacies
10:50
to
12:20
Knowledge market 3 (K3)
Birgitte Thylstrup
Oral presentation
Primary Care Provider expectations of addiction services and patients in Spain.
10:50
to
12:20
Knowledge market 3 (K3)
Pablo Barrio
Oral presentation
Optimising take home naloxone intervention delivery in the community (retail) pharmacy setting.
10:50
to
12:20
Knowledge market 3 (K3)
Jennifer Scott
Oral presentation
Practitioner perspectives on working with older patients in opioid agonist treatment (OAT) in Norway
10:50
to
12:20
Knowledge market 3 (K3)
John Todd-kvam
Oral presentation
Integrating harm reduction in homelessness services. The HR4H Key Principles
10:50
to
12:20
Knowledge market 3 (K3)
Roberto Perez Gayo
13:20
Short communication
Z-Drugs Dependence: An Awakening Truth
13:20
to
14:50
Networking zone 3 (N3)
Afonso Homem De Matos
Short communication
Evaluating Cracks in the Ice – a digital health initiative to support families, health workers and communities affected by crystal methamphetamine (‘ice’)
13:20
to
14:50
Networking zone 3 (N3)
Steph Kershaw
Short communication
Exclusive therapeutic use of cannabis in France: characteristics and use patterns in a large sample of daily users
13:20
to
14:50
Networking zone 3 (N3)
Martin Bastien
Short communication
Psychoactive substance use among Serbian adults – results from online survey
13:20
to
14:50
Networking zone 3 (N3)
Biljana Kilibarda
Short communication
Harm Reduction for Chemsex in Lisbon: community-based interventions for a hard-to-reach group, during the COVID-19 pandemic
13:20
to
14:50
Networking zone 3 (N3)
Filipe Couto Gomes
Short communication
The epigenetic effects of cannabis exposure and their link to behavior and emotional manifestations – a scoping review
13:20
to
14:50
Networking zone 3 (N3)
Ana Sofia Machado
16:50
Oral presentation
Medical cannabis regulation: Taking the best of the North American and European models
16:50
to
18:20
Insights zone 2 (I2)
Davide Fortin
Oral presentation
Municipal variations in cannabis regulation regarding public consumption and retail sales in Canada
16:50
to
18:20
Insights zone 2 (I2)
Christophe Huynh
Oral presentation
Québec's public, not-for-profit cannabis distribution regime: a comparative analysis, three years in
16:50
to
18:20
Insights zone 2 (I2)
François Gagnon
Oral presentation
Regulating Cannabis for Public Health
16:50
to
18:20
Insights zone 2 (I2)
Seema Pessar
Oral presentation
Mitigating the risks of corporate capture in emerging legal cannabis markets
16:50
to
18:20
Insights zone 2 (I2)
Stephen Rolles
Oral presentation
Equity in Marijuana Policies: A Comparative Study of two U.S. States using Critical Race Theory.
16:50
to
18:20
Insights zone 2 (I2)
Gaby Mohr
Oral presentation
Differences in cannabis use and opinions on drug policy between generations
16:50
to
18:20
Central square 2 (C2)
Pekka Hakkarainen
Oral presentation
Adolescent cannabis use during a period of rapid policy change: Evidence from the US PATH Study
16:50
to
18:20
Central square 2 (C2)
Mike Vuolo
Oral presentation
The role played by evidence on the effects of cannabis use in cannabis policy 1992-2022
16:50
to
18:20
Central square 2 (C2)
Eva Hoch
Oral presentation
Trajectories of Prescribed Medical Cannabis Filled Over Time
16:50
to
18:20
Central square 2 (C2)
Alexandra Kritikos
Friday, 25 November
13:20
e-poster
Non-prescribed buprenorphine and reduction in illicit opioids use among individuals with opioid use disorder: a longitudinal study
13:20
to
14:50
Networking zone 2 (N2)
Raminta Daniulaityte
e-poster
Sexualized substance use, consumption motives and risk factors for relapse of addiction patients. Results of a cross-sectional study in addiction treatment facilities in Germany.
13:20
to
14:50
Networking zone 2 (N2)
Daniel Deimel
e-poster
How hair keeps track: Associations between hair concentrations of psychoactive substances and steroid hormones in a large cohort sample of young adults in Switzerland
13:20
to
14:50
Networking zone 2 (N2)
Lydia Johnson-Ferguson
e-poster
Four-year long wastewater-based monitoring of illicit drug consumption pilot project in Switzerland
13:20
to
14:50
Networking zone 2 (N2)
Livia Andrani
e-poster
How are profiles of substance use linked to social function in the following seven years?
13:20
to
14:50
Networking zone 2 (N2)
Sidsel Karsberg
e-poster
A systematic review of self-report and behavioural measures of the Addiction Neuroclinical Assessment constructs of incentive salience and negative emotionality, in adults who use psychoactive drugs.
13:20
to
14:50
Networking zone 2 (N2)
Maria Bravo Aguilera
e-poster
Changes in substance use during the COVID-19 pandemic: Longitudinal analysis of risk behavior and mental health of MSM using HIV pre-exposure prophylaxis
13:20
to
14:50
Networking zone 2 (N2)
Babette Lea Winter